Maspin has been identified as a potent angiogenesis inhibitor. However, the molecular mechanism responsible for its anti-angiogenic property is unclear. In this study, we examined the effect of maspin on endothelial cell (EC) adhesion and migration in a cell culture system. We found that maspin was expressed in blood vessels ECs and human umbilical vein endothelial cells (HUVECs). Maspin significantly enhanced HUVEC cell adhesion to various matrix proteins. This effect was dependent on the activation of integrin β 1 , which subsequently led to distribution pattern changes of vinculin and F-actin. These results indicated that maspin affects cell adhesion and cytoskeleton reorganization through an integrin signal transduction pathway. Analysis of HUVECs following maspin treatment revealed increased ILK activities and phosphorylated FAK levels, consistent with increased cell adhesion. Interestingly, when HUVECs were induced to migrate by migration stimulatory factor bFGF, active Rac1 and cdc42 small GTPase levels were decreased dramatically at 30 minutes following maspin treatment. Using phosphorylated FAK at Y397 as an indicator of focal adhesion disassembly, maspin treated HUVECs had elevated FAK phosphorylation compared to the mock treated control. The results were a reduction in focal adhesion disassembly and the retardation in EC migration. This study uncovers a mechanism by which maspin exerts its effect on EC adhesion and migration through an integrin signal transduction pathway.
Angiogenesis is required for tumor growth and metastasis. Blood vessels in solid tumor are composed of endothelial cells and tumor cells.
These mosaic vessels allow for the shedding of tumor cells into the vasculature and transport of tumor cells to the second site through circulation system. Identifying angiogenic growth factors and inhibitors and characterizing their contribution to endothelial cell migration and proliferation will not only help us to gain insight of the biology of angiogenesis network, but also provide potential candidates for developing more efficient cancer therapeutic strategies targeting angiogenesis.
Our laboratory identified maspin as a potent angiogenesis inhibitor (1) . Its anti-angiogenic property was later confirmed by Cher et al. in a model of prostate cancer (2) . Maspin is a member of serine protease inhibitor (Serpin) with tumor suppressing function. It is a 42 kDa protein produced by many cell types from mammary gland, prostate, skin, and cornea (3, 4) . Structurally, maspin belongs to the family of serine protease inhibitors with homology to plasminogen activator inhibitor 1 and 2 (PAI-1 and PAI-2), and ovalbumin. However, unlike PAI-1 and PAI-2, maspin does not directly inhibit serine proteases (5, 6) . As a tumor suppressor, maspin functions to inhibit tumor cell migration and invasion, and induces tumor cell apoptosis (7) (8) (9) (10) .
For many years, it has not been clear how maspin controls angiogenesis, especially how maspin regulates endothelial cell (EC) motility. ECs can be activated by exogenous stimuli such as bFGF and VEGF and produce matrix metalloproteinases (MMPs) to degrade matrix surrounding ECs. ECs could escape from the vessel walls and invade into surrounding tissue and also proliferate to form solid sprouts connecting neighboring vessels. Cell adhesion and migration govern the escape of ECs from original vessel structures. Many molecules produced by ECs or surrounding tissue regulate this process. Integrin family plays important role in EC adhesion process. Thus, it is not surprising that molecules affecting the interaction between integrins and EC matrix will likely regulate angiogenesis and EC function. In fact, several proteins that regulate integrin-mediated cell adhesion emerge as key modulators of vascular functions (6, 11, 12) .
This study identifies a new molecular mechanism by which maspin controls angiogenesis. Previously, our laboratory showed that maspin interacts with integrin β 1 in mammary epithelial cells (10) . In this study, we have provided direct evidence that maspin inhibits angiogenesis through controlling EC cell adhesion, migration, and adhesion-mediated cell signaling pathway. In particular, we have shown that maspin increases endothelia cell adhesion to fibronectin (FN), laminin (LN), collagen (Col) and vitronectin (VN), which in turn activates integrin β 1 , ILK and FAK signal transduction pathway. Subsequent changes in focal adhesion and cytoskeleton reorganization result in the attachment and spreading of ECs on matrix. Furthermore, we discovered that maspin also blocked EC cell migration by disrupting focal adhesion disassembly. This report identifies maspin as one of the key molecules that play a key role in EC cell adhesion and migration.
Experimental Procedures Cell culture and reagents
Human umbilical vein endothelial cells (HUVEC) were cultured in EBM medium, and harvested when cells reached 70-80% confluent. Anti-Rac1 and anti-ILK antibodies, MBP protein was obtained from Upstate, Inc., vinculin antibody and collagen from Sigma-Aldrich, anti-integrin α v β 3 (LM609), anti-integrin β 1 (AIIB2) is a kind gift from Dr. Karl S. Matlin. Vitronectin was obtained from Chemicon. Anti-active integrin β 1 was from BD Pharmingen and anti-cdc42 from Santa Cruz Biotechnology. Laminin-1 was purchased from Invitrogen, and fibronectin was from GIBCO. Other cell culture reagents were from Sigma-Aldrich unless otherwise noted. GST-Maspin is mouse maspin fused to GST as described previously (7) . Preparations of GST-Maspin and GST followed the procedure as described (7) . Recombinant proteins were pre-treated with polymyxin B beads and dialyzed against PBS before being used in cell culture.
Immunocytochemistry
Mouse embryonic yolk sac samples at E9.5 were fixed and sectioned to 5 µM slides. Anti-maspin antibody (ABS4A, 0.25 µg/µl, 1:250) was used for immunostaining as described before (13) . Maspin immunostaining in HUVECs was done using the same ABS4A antibody at the same concentration and a Texas Red conjugated secondary anti-rabbit antibody. Cells were counter-stained with DAPI. For vinculin and integrin β 1 immunostaining, HUVECs were first serum-starved for 4 hours and detached by 0.05% trypsin EDTA. After incubating with 0.5 µM GST-Maspin or GST protein in serum free EBM medium for 30 minutes, cells were seeded to FN-coated cover slips for 30 minutes with or without bFGF. Then cells were fixed in 4% PFA and permeabilized with 0.5% Triton X-100. For nocodazole-treated group, serum-starved HUVECs were first incubated with 10 nM nocodazole for 4 hours and then were treated with 0.5 µM GST-Maspin or GST, and fixed with 4% PFA at 0, 15, 30, 60, and 120 minutes respectively. Fixed cells were incubated with antibodies against vinculin (1 µg/µl, 1:200) or active integrin β 1 (0.5 µg/µl, 1:100) at 4ºC overnight, followed by incubation with appropriate second antibodies labeled with FITC or Texas Red. Nuclei were stained by DAPI. Images were acquired with a 100x objective using a Zeiss fluorescence microscope.
Immunoprecipitation and Western blot analysis
HUVEC cells were serum-starved for 4 hours, detached with 0.05% trypsin, and then incubated with GST-Maspin or GST for the indicated time at 37ºC with 5% CO 2 . After lysing cells with RIPA buffer (0.05 M Tris-HCl, pH 7.6, 0.15 M NaCl, 1% NP-40, 0.5% deoxycholate, 2 mM EDTA and protease inhibitor cocktail), cell extracts were subjected to immunoprecipitation with an anti-PY20 antibody and separated by 8% SDS-PAGE gel, followed by transferring to immuno-blot PVDF membrane (Bio-Red). Western blot analysis was performed using anti-phosphorylated FAK antibody and blots were visualized with chemiluminescence (Pierce Biotechnology, Inc.). For the quantitation of active Rac1 and cdc42, starved HUVECs were pre-incubated with bFGF (20 ng/ml) prior to GST-Maspin or GST treatment.
Cell extracts were immunoprecipitated with PAK1 and immunoblotted with anti-Rac1 or anti-cdc42
antibodies. An anti-pY397FAK antibody was used to detect phosphorylated FAK at Y397 site. An anti-FAK antibody against total FAK was purchased from BD-PharMingen and used at the dilution of 1:200 (0.2 µg/µl). Maspin Western immunoblot analysis was done using a mouse raised maspin polyclonal antibody as described previously (10) .
Adhesion assay

Nunclon
TM 96-well flat-bottom polyvinyl chloride plates (Nunc TM , Roskilde, Denmark) were covered with FN, LN, Col or VN at 15 µg/ml or indicated concentrations, and then blocked with 1% BSA for 30 minutes. Serum-starved HUVEC cells were detached with 2 mM EDTA and re-suspended in serum free EBM medium at a density of 5x10 4 cells/ml. Cells were then incubated with GST-Maspin or GST at a concentration of 0.5 µM at 37ºC for 30 minutes. In the antibody-blocking assay, cells were firstly incubated with anti-maspin polyclonal rabbit antibody (0.5 µg/µl, 1:200) or anti-β1 antibody (AIIB2, 0.2 µg/µl, 1:80) for 20 minutes before GST-Maspin or GST treatment, and then added to the matrix-coated plates, followed by incubation at 37ºC for 0.5 hour. After washing the plate with PBS to remove unattached cells, the adhered HUVEC cells were fixed with 4% PFA for 30 minutes and then stained with 0.2% crystal violet in 10% ethanol. The violet stain was solubilized with 1:1 (v:v) 0.1 M NaH 2 PO 4 (pH 4.5) and ethanol, and absorbance was measured at 540 nm with a microplate reader.
ILK assay
ILK kinase assay was performed using a rabbit immunoaffinity-purified ILK antibody (Upstate Biotechnology, Lake Placid, NY). Myelin basic protein (MBP) served as the substrate and could be phosphorylated by active ILK. HUVECs were first incubated with GST-Maspin or GST for 1 hour and then lysed in RIPA buffer. Cell extract (500 µg) were immunoprecipitated by protein A-agarose beads, which were conjugated with ILK antibody. After washing the beads with lysis buffer for once and with kinase buffer twice [50 
Maspin knock down by RNA interference
Selected maspin siRNAs (229 and 455) were cloned into pSUPER.retro.puro vector (Oligo Engine) as previously described (10) and transfected into PT67 packaging cells. Supernatants containing virus were added to HUVEC cells for 2 days in the presence of 2 µg/ml of polybrene. Empty pSUPER.retro and siRNA negative-control (sequence 1; Ambion) were used as negative control. After infection for two days, cells were selected with 1 µg/ml of puromycin. Maspin knockdown efficiency was evaluated by Western blot analysis using a maspin polyclonal antibody as described previously (10) . Pooled cells of siRNA stable clones were used in the adhesion assays.
Cell motility assay
Cell motility assay were performed with a HitKit (Cellomics, Inc) assay as described (Qin, 2009). Briefly, blue fluorescent beads were added to wells of 96-well plate pre-coated with FN (1.5 µg/well). After incubating the plate in the dark at 37ºC for 60 minutes, the extra beads were removed with PBS buffer. HUVECs were pre-treated with 0.5 µM GST-Maspin or GST respectively with or without bFGF, and were plated to the wells of 96-well plate at the density of 1.0x10 4 cells/ml. After incubation for 2, 7, and 18 hours at 37ºC with 5% CO 2 , cells were fixed with 5.5% formaldehyde for 60 minutes and stained with a Rhodamine-Phalloidin. Images from five randomly selected areas were taken for each sample under a Zeiss fluorescent microscope and the track areas were quantitatively analyzed using a NIH image J software.
Focal adhesion disassembly assay
Focal adhesion disassembly assay was performed as described (14) . Briefly, nocodazole was applied to activate Rho GTPase and stimulate the formation of focal adhesion and stress fibers in the cells. After nocodazole treatment, cells were washed with PBS and focal adhesion started to disassemble. Starved HUVECs were incubated with 10 nM nocodazole for 4 hours. After washing out the drug with PBS, cells were incubated with 0.5 µM GST-Maspin or GST, and then fixed with 4% PFA at 0, 15, 30, 60, and 120 minutes time points, followed by permeabilization with 0.5% Triton-X100. For Western blot analysis, starved cells were first treated with 10 nM nocodazole for 4 hours and incubated with 0.5 µM GST-Maspin or GST for the indicated time as above. Cells were lysed with RIPA buffer and extracts were separated in 10% SDS-PAGE gel to determine the level of phosphorylated pY397-FAK.
RESULTS
Maspin is expressed in endothelial cells and acts to increase endothelial cell adhesion
Maspin is known to be expressed in the epithelial cells of the mammary and prostate glands (15) . Consistently, we also detected expression of maspin in embryonic endothelial cells and stromal cells in blood islands by immunohistochemistry (Fig. 1A) . In cultured human umbilical endothelial cells (HUVECs), positive maspin signals were observed in the cytoplasm in a punctate staining pattern (Fig.  1C) . Additionally, Western blotting analysis revealed maspin expression in HUVECs (Fig.  1E) .
Secreted maspin may act on the surface of ECs to regulate cell adhesion, in a manner similar to mammary epithelial-derived maspin that acts on cell surface to modulate adhesion to laminin 1-rich matrix (2, 10) . To test this possibility, we seeded HUVECs in wells pre-coated with FN and treated cells with different concentrations of recombination GST-Maspin or GST. Maspin treatment enhanced cell adhesion on FN in a concentration-dependent manner. The enhanced cell adhesion peaked with 0.5 µM GST-Maspin treatment (Fig. 1F) .
To examine the effect of maspin on HUVEC adhesion on different matrix, HUVEC cells were seeded in wells pre-coated with FN (15 µg/ml), LN (2 µg/ml), Col I (15 µg/ml) and VN (1 µg/ml), and treated with 0.5 µM of GST-Maspin or GST protein. Maspin significantly enhanced HUVEC cell adhesion to these matrixes with varied effects (Fig. 1G ). To determine whether the enhanced cell adhesion is caused by the interaction of exogenous GST-Maspin on cell membrane not the endogenous maspin, HUVEC-derived maspin was knocked down by RNA interference. Western blot analysis showed that maspin was knocked down efficiently (80% reduction) in HUVECs (Fig. 1I ), and these HUVEC-siRNA maspin cells displayed significant reduction in cell adhesion (90% of wildtype HUVECs). However, when HUVEC-siRNA maspin cells were treated with GST-Maspin they responded with enhanced cell adhesion, similar to the HUVEC-siRNA control and wildtype HUVECs (Fig. 1H ).
Previous reports showed that different regions of maspin protein participated in the regulation of cell migration, depending on the cell types and matrix contexts (16, 17) . To determine whether reactive site loop (RSL) or other regions of maspin is involved in HUVEC cell adhesion, several maspin mutants were tested by adhesion assay ( Fig. 2A) . A deletion mutant Mp (1-139 aa) abolished maspin's effect on HUVEC cell adhesion. Mp (140-375 aa) retained most of the maspin's enhancing effect on adhesion (Fig. 2B ), suggesting the region of 140-375aa may play the important role in cell adhesion. Mp (1-225aa) slightly enhanced HUVEC adhesion (Fig. 2B ). Previous studies showed that maspin RSL domain plays role in regulating breast cancer cell migration (17). Arginine 340, located in the RSL motif in maspin, is critical for its interaction with uPA and involved in regulating cell migration (18) . To test the role of this region in cell adhesion, we generated maspin mutants with deletion of C-terminus containing RSL domain and a mutant with point mutation at 340 aa (Arg to Ala) in RSL region. Cell adhesion assay showed that both mutants could enhance HUVEC cell adhesion, but at a reduced level compared to wild-type maspin ( Fig. 2A & B) . Using a polyclone anti-maspin antibody (raised against the full length of maspin protein) we found that cell adhesions on both FN and LN were significantly blocked by this antibody (Fig. 2C  & D) . These findings confirm the specific enhancement of cell adhesion by maspin.
Maspin activates integrin β 1 signal transduction pathway in endothelial cells
Integrins play an important role in cell adhesion. To address whether exogenous maspin affects cell adhesion through integrin, we examined the activation status of integrin following maspin treatment. Since integrin α 5 β 1 mediates cell adhesion on FN, we first examined whether integrin β 1 was involved in maspin-mediated HUVEC cell adhesion on FN. Activation of integrin β 1 can be detected with a unique β 1 antibody that recognizes the activated β 1 present within integrin clusters (19) . Immunocytochemical analysis, using this specific antibody, showed that integrin β 1 was rapidly activated following the treatment of GST-Maspin. Notably, formation of integrin cluster was observed throughout the surface of HUVECs following GST-Maspin treatment (Fig.  3A) . As a control, GST treatment did not activate integrin β 1 in HUVECs (Fig. 3B) . On average, there were 3 sites of clustered integrins observed on each HUVEC treated with GST (n=8). On the contrary, the GST-Mapsin treated HUVECs contained 22 clusters per cell (n=10)(p <0.05). In general, clustered integrins (indicative of activation) are presented on the protuberant edge of cells, a requirement for focal adhesion formation. However, GST-Maspin treated HUVECs displayed a unique pattern of activated integrin β 1 .
The distribution of activated integrin β 1 , in GST-Maspin-treated HUVECs, was in a non-polarized manner (Fig. 3A) .
To further confirm the activation of integrin β 1 by maspin, we employed an anti-integrin β 1 blocking antibody (AIIB2) to determine whether it could abolish maspin-mediated enhancement of cell adhesion on FN. HUVECs were pre-incubated with AIIB2 antibody for 60 minutes and then treated with GST-Maspin or GST. As expected, AIIB2 antibody treatment completely blocked maspin-mediated enhancement of cell adhesion. On the contrary, when HUVECs were first treated by GST-Maspin and then incubated with the AIIB2 antibody, the antibody no longer blocked the enhanced cell adhesion by GST-Maspin (Fig.  3C) . Similar results were observed in another adhesion assay using laminin 1 (LN) as the matrix (Fig. 3D) .
Integrin signal is transferred from outside into the intracellular compartment through integrin cytoplasmic tail. The cytoplasmic tail of integrin β 1 interacts with integrin-linked kinase (ILK), which subsequently phosphorylates a series of signaling molecules in downstream pathway. In particular, ILK could phosphorylate a myeline basic protein (MBP), which can be used as substrate in ILK kinase assay. If maspin activates HUVEC integrin β 1 , ILK activity should be increased following GST-Maspin treatment. Using MBP as the substrate in the ILK assay, we found that extracts from GST-Maspin-treated HUVECs can phosphorylate more MBP compared to the GST-treated HUVECs group (Fig. 3E) , indicating that GST-Maspin treatment increased ILK activity in HUVECs. Integrin activation leads to phosphorylation of focal adhesion kinase (FAK). FAK is a cytoplasmic non-receptor protein tyrosine kinase, whose phosphorylation is required by downstream signaling in many cell types. To examine the effect of maspin on phosphorylated FAK in HUVECs, cell extracts harvested from GST-Maspin or GST treated HUVECs were subjected to immunoprecipitation with an anti-FAK antibody and blotted with PY20 antibody which recognizes all tyrosine phosphorylated proteins. We found that the level of phosphorylated FAKs was increased at 30 minutes following GST-Maspin treatment, which returned to the base line at 60 minutes (Fig. 3F) .
Maspin modulates the rearrangement of cytoskeleton in HUVECs
One of the cellular responses to integrin activation is cytoskeleton reorganization. Vinculin is a cytoskeletal protein that stabilizes the interaction between talin and actin or talin and membrane. By immunofluorescence staining, we found that vinculin pattern changed drastically in maspin-treated HUVECs. In particular, we found that in GST-Maspin treated HUVECs, the discontinuous acicular signals were observed in 30% cells (n=50) and distributed along the periphery of HUVECs at 30 minutes following treatment (Fig. 4A) . However, at 60 minutes, 70% of cells (n=50) exhibited the acicular signals and the density of signals became much stronger compared to 30 minutes (Fig. 4B) . The strength of acicular signals retained the same intensity in 70% cells at 120 minutes time point (n=50) (Fig. 4C) . On the contrary, in GST-treated control group, less than 10% cells were observed with very weak signals surrounding the cell periphery at 30 minutes (n=50) (Fig. 4D) . There was no increase in the number of positive cells nor in the signal intensity in GST-treated HUVECs at 60 or 120 minutes time point (Fig. 4E & F) .
Phalloidin is used to monitor the changes of actin cytoskeleton in GST or GST-Maspin treated HUVECs. We found that GST-Maspin treatment in HUVECs led to rapid formation of microfilaments, which extended into focal adhesions at 30 minutes. Abundant thin filaments were distributed in cytoplasm (Fig.  4G ). Up to 60 minutes post-GST-Maspin treatment, more microfilaments formed and extended into focal adhesions which were distributed in a radial-like pattern along cell peripheral in an unpolarized manner (Fig. 4H ). There were more thin filaments distributed in cytoplasm as compared to the control cells at the same time point. Even at 120 minutes after GST-Maspin treatment, there were still more numbers of microfilaments and thin filaments observed as compared to the control treated HUVECs (Fig. 4I) , suggesting that GST-Maspin treatment led to reorganization of cytoskeleton, which facilitates cell adhesion and subsequent spreading on matrix. GST treatment led to different F-actin pattern in HUVECs. Linear F-actin filaments and very few microfilaments were observed scattered in cytosol of HUVECs at 30 minues (Fig. 4J) . Up to 60 minutes, microfilament amount in cells increased. Most of them were surrounding the nuclei and a small portion extended into focal adhesions that were distributed in a polarized manner. There were also some thin filaments in the cytoplasm (Fig.  4K) . At 120 minutes of GST treatment, microfilaments in cells were decreased, while a small amount of thin filaments with weak staining were observed scattered in the cytoplasm (Fig. 4L) .
Maspin inhibits HUVEC cell migration on extracellular matrix
Cell migration is a complex process, including delicate control of cell adhesion, disassembly of adhesion, and changes of cytoskeleton. The effect of maspin on HUVEC cell migration was examined by monitoring the migration track of cells on the matrix following GST-Maspin or GST treatment at different time points (2, 7, 18 hours) with or without bFGF. GST-Maspin treatment significantly reduced HUVEC cell migration rate at all time points (Fig. 5A panels a, b, c, d , e and f). However, in the presence of bFGF, GST-Maspin treatment exhibited much stronger inhibition on cell migration with a decrease of over 50% of migration area compared to the GST treatment ( Fig. 5A panels g, h, i, j, k and l) .
We also examined the pattern of focal adhesion complex in HUVECs treated with bFGF and GST-Maspin or bFGF and GST. Using vinculin immunofluorescence staining, we monitored the changes of focal adhesion in these HUVECs. In GST-treated HUVECs stimulated with bFGF, focal adhesions were present in a polarized pattern of distribution. Punctate vinculin signals were located at migrating edge of the HUVECs. However, HUVECs treated with GST-Maspin and bFGF displayed a non-polarized, immobile pattern (data not show).
Cell migration is generally associated with the increase of active Rac1 and cdc42. We further examined Rac1 and cdc42 Rho GTPase levels in HUVEC cells following GST-Maspin or GST treatment. In accordance with the pattern of focal adhesion, we found that both active Rac1 and cdc42 levels in HUVECs were significantly reduced at 30 minutes with GST-Maspin treatment, but the reduction was transient. At 60 minutes, their levels began to ascend slightly. However, in GST treated control cells, active Rac1 and cdc42 levels were increased starting from 15 minutes and peaked at 30 minutes, which is a typical response since cells are responding to bFGF stimulation (Fig.  5B) .
Maspin disrupts focal adhesion disassembly
Cell migration is a cyclic process that involves both the adhesion at the protrusive end and the disassembly of focal adhesion at the cell rear. Maspin may inhibit cell migration by promiscuously enhancing cell adhesion at all ends and impairs focal adhesion disassembly at the cell rear. To test this hypothesis, we utilized an established method (14) to analyze maspin-mediated effect on focal adhesion disassembly. After nocodazole treatment, cells were washed with PBS and focal adhesion started to disassemble. We found that starved HUVECs formed abundant focal adhesions when incubated with 10 nM nocodazole for 4 hours (Fig. 6A) . In the absence of nocodazole, only a few focal adhesion signals were observed in starved cells (Fig. 6B) . After nocodazole washout, focal adhesions rapidly disassembled in HUVECs. As shown in Fig. 6 , GST-treated HUVECs exhibited the loss of focal adhesion complex dramatically during the time period from 15 to 60 minutes after nocodazole washout (Fig. 6D, F, & H) . Focal adhesions became apparent again 120 minutes after nocodazole washout (Fig. 6J) . Alternatively, GST-Maspin treated HUVECs retained a high level of focal adhesions as indicated by vinculin staining at 15 minutes after nocodazole washout (Fig. 6C) . Compared with the GST-treated control cells, the disassembly of focal adhesion was greatly impaired at 30, 60, and 120 minutes following nocodazole washout (Fig. 6E, G, J (15) . After nocodazole washout, pY397-FAK levels decreased steadily from 0 to 2 hours in GST-treated HUVECs. However, GST-Maspin treated HUVECs maintained the pY397-FAK levels during these corresponding time points (Fig. 6K) . Collectively, these results suggest that GST-Maspin treatment maintains FAK phosphorylation (Y397), which might contribute to the observed impairment of focal adhesions disassembly.
DISCUSSION
Maspin is widely expressed in epithelial cells of many tissues, including mammary gland (3, 9) , prostate (20) , intestine (3), and lung (21), and in non-epithelial corneal cells as well as prostate stromal cells (4) . In breast tumors, maspin expression is down regulated and the loss of maspin is correlated with a decrease in tumor invasiveness (8) . In this study, we detected the expression of maspin in ECs and smooth muscle cells in vessels of embryonic yolk sac tissue and in cultured HUVECs (Fig. 1) . Impagnatiello et al. reported that maspin was expressed in neovascular endothelial cells (22) . Our laboratory first reported that maspin acted as a potent angiogenesis inhibitor (1). Cell-ECM interactions between endothelial cells (EC) and the matrix proteins play a central role in many processes involved in normal vascular development and angiogenesis, including cell signaling, proliferation, and differentiation. The significance of this study is that we have discovered a new mechanism by which maspin controls endothelial cell-ECM adhesion and angiogenesis. Thus, it is very possible that we can target maspin for blocking angiogenesis and treating other vascular diseases.
Our data suggest that maspin may be secreted from ECs or smooth muscle cells, and can affect EC property through cell membrane receptor(s) signaling. Other studies have supported this claim that secreted maspin can function at the cell surface in an autocrine and/or paracrine manner (17, 19, 23, 24) . For example, in prostate tumor cells, maspin inhibits prostate cancer cell migration through increased cell adhesion to various extracellular matrices (19) . In MCF-10A human mammary epithelial cells, maspin increased mammary cell adhesion to the self-deposited laminin 5 matrix (10) . Others showed that maspin regulated cell motility and adhesion in aggressive breast cancer cells through different signaling pathways (17, 25) . To determine the effect of maspin on EC cells, we treated wildtype HUVECs or maspin silenced HUVECs with recombinant GST-Maspin or GST control. We found that maspin increased cell adhesion on FN, LN, Col, and VN in a concentration dependent manner. We noticed that in HUVEC-siRNA maspin cells, maspin treatment has a similar enhancing effect on cell adhesion as that in the wildtype HUVECs. Moreover, this enhancing effect could be blocked by an anti-integrin β 1 antibody. It is well known that integrins mediate cell adhesion on matrix through RGD domain. ECs express multiple integrins, including α v β 3 , α 6 β 1 (26) , α 3 β 1 (27) , α 5 β 1 (28) , and α 2 β 1 (29) . Thus, it is possible that maspin could enhance cell adhesion by activating the integrin signaling pathway. Our laboratory previously demonstrated that maspin interacts in a complex with integrin β 1 to enhance mammary epithelial cell adhesion (10) . Additionally, integrin β 1 was activated in HUVECs following maspin treatment,. More recently, Bass et al., showed that maspin interacted with integrin β 1 in vascular smooth muscle cells (VSMC) (23) . Together, these studies strongly suggest that maspin can control cell adhesion through activation of integrin β 1 .
Integrins are transmembrane proteins with cytoplasmic tails that are associated with adaptor proteins, linking integrins with cytoskeleton, cytoplasmic kinases, and transmembrane growth factor receptors (30) . Binding of integrin to extracellular ligand causes focal clustering of integrin receptors, resulting in integrin activation (19) . Integrin activation triggers integrin linked kinase (ILK), a serine-threonine kinese, which can interact with cytoplasmic domain of integrin β 1 and β 3, and transfer the outside-in signal (31) . In our study, we found that maspin treatment increased ILK activity of HUVEC cells within 30 minutes, suggesting that maspin could activate ILK through integrin signaling. ILK is a PI 3 K-dependent kinase, which controls PKB/Akt phosphorylation on serine 473 (32) (33) (34) (35) . It possesses a binding domain for paxillin, affixin, and PINCH, and together modulate actin cytoskeleton inside the cell (36) . Reducing ILK expression and suppressing ILK activity restrain cell attachment through modulating intracellular F-actin organization and CH-ILKBP/paxillin localization (37) . Here, we showed that maspin potentiated ILK activity of HUVECs (Fig. 3D) , suggesting that maspin also activates the integrin pathway. Increased ILK activity is positively correlated with enhanced HUVEC cell adhesion and spreading on matrix.
Cell movement is a complex process, involving the extension of the plasma membrane at cell front and subsequent stabilization of nascent cell-matrix adhesion formed at the tips of membrane protrusions through the interaction between integrin and ECM. Intracellular signals from integrins induce the formation of a focal adhesion complex, and modulate the dynamics of actin filament for further membrane extension (38) . Vinculin, a cytoskeleton protein localized in focal adhesion complex, contains the binding sites for talin and α-actinin in globular head region, as well as, the binding sites for F-actin and paxillin in its rod-like tail domain. Vinvulin possesses the ability to mediate interactions between integrins and the cytoskeleton at focal adhesions. This is important for control of cytoskeleton reorganization, cell spreading, and lamellipodia formation (39, 40) . In this study, we found that maspin treatment led to vinculin pattern change in HUVECs, suggesting that there was a re-arrangement of the cytoskeleton and focal adhesion formation following maspin treatment.
Focal adhesion complex assembly and disassembly are critical for cell adhesion and migration. Focal adhesion kinase (FAK) plays a central role during this process. Integrin activation results in FAK phosphorylation at Y397 site. When FAK is activated, it is autophosphorylated, binds to Src, which in turn phosphorylates other sites on FAK and the FAK-binding proteins, such as Cas and paxillin, which modulates cytoskeleton re-arrangement (41) . Abrogation of FAK phosphorylation greatly impaired cell spreading and adhesion (42) . In this study, we found that the increased focal adhesion following maspin treatment was accompanied by the enhanced FAK phosphorylation in HUVECs, which is in accordance with evidence that the level of phosphorylated FAK increases during focal adhesion formation (43) . Additionally, FAK interacts with other cytoplasmic signaling molecules (44, 45) . For example, FAK phosphorylation leads to phosphorylation of PKL (paxillin kinase linker) through Src and facilitates the recruitment of PKL to the focal adhesion complex for paxillin binding, which is required for the localization of focal adhesion complex, cell spreading, and membrane protrusion (46) . It is possible that maspin may also activate FAK signal transduction pathway and recruit those molecules to the focal adhesion complexes and facilitate cell spreading.
Rho family of small GTPases is one of the downstream targets of integrin and FAK (47) . Rho family proteins control cell migration by balancing the activities between RhoA, Rac1 and other Rho-kinases, modulating cell attachment, migration, and early actin network-formation (26, 48) . Rac1 influences the formation of nascent focal complexes at the leading edge (49) . It activates Arp2/3 complex and regulates the de novo branching of actin filaments at the leading edge, resulting in the formation of lamellipodia (50) . The unidirectional lamellipodia formation is often observed when endothelial cells are treated with angiogenic growth factors or chemokines, which is accompanied with a transient increase of Rac1 and cdc42 small GTPases activities. In this study, we observed that bFGF stimulated Rac1 and cdc42 activities as early as 15 mins and increased endothelialcell migration through the formation of filopodia and lamellipodia at the leading edge. However, maspin treatment resulted in the transient reduction of Rac1 and cdc42 activities at 30 minutes (Fig. 5B ) and restricted the unidirectional formation of filopodia and lamellipodia in HUVECs (data not shown), which led to the repressed cell migration (Fig.  5A ). Of note, the concentration of angiogenic factor bFGF added was very high. Under this situation, the inhibitory effect of maspin was gradually reversed at 60 minutes. However, under physiological conditions with lower level of angiogenic factors, maspin's inhibitory effect may last much longer. Interesting, Bass et al. also showed that maspin regulated VSMC migration through integrin β 1 . They found that VSMCs treated with maspin for 60 minutes caused a decrease of active β 1 (23) . However, our study of HUVECs analyzed cell adhesion at much earlier signaling stages (0, 15, 30 minutes) following maspin treatment. It is possible that HUVECs treated with maspin for a longer time may also cause a decrease of integrin β 1 activation, due to a desensitization of integrin signaling.
Cell migration involves not only the adhesion at the leading edge but also the disassembly of focal adhesion at the rear end. In response to angiogenic factors, endothelial cells first attach to certain matrix proteins at the leading edge to form focal adhesion. Subsequently, cell translocates forward and forms a new leading edge and new cell-matrix adhesion at the tips of membrane protrusions. Cell migration occurs when there is a turnover/disassembly of previous focal adhesions. Based on our studies, we found that maspin inhibited bFGF-induced cell migration by two mechanisms. First, maspin enhanced focal adhesion formation in HUVECs. Second, maspin blocked the turnover/disassembly of focal adhesion. In this study, we used a well-established focal adhesion turnover model to test the effect of maspin on focal adhesion turnover/disassembly (Fig. 6) . Nocodazole treatment activates Rho GTPase and stimulates formation of focal adhesion and stress fibers (39, 51) . After nocodazole washout, focal adhesions disassemble. We found that compared with the mock-treated cells, focal adhesion disassembly was reduced in maspin-treated HUVECs. One key assay that measures focal adhesion disassembly is to examine the level of phosphorylation of FAK (Y397) in nocodazole treated cells. In a previous report, Ezratty et al. showed that the level of pY397-FAK was significantly reduced during the process of focal adhesion disassembly. After a 2-hour washout of nocodazole, pY397-FAK levels were increased in conjunction with newly formed focal adhesion complexes (14) . We observed that the new focal adhesion was formed in control group of HUVECs 2 hours after nocodazole washout, which was accompanied with the increased pY397-FAK levels. However, in maspin treated HUVECs, we did not observe focal adhesion disassembly after nocodazole washout. Rather, we found that pY397-FAK in HUVECs treated with maspin was maintained at a much higher level compared to the mock treated HUVECs. This high level of pY397-FAK prevented focal adhesion disassembly, leading to restricted cell migration. The level of pY397-FAK was reduced 2 hours after nocodazole washout, which was significantly delayed compared to mock-treated HUVECs, suggesting that maspin treatment slows focal adhesion disassembly resulting in impaired cell migration (Fig. 6 ).
In accordance with the above results, we also observed that maspin-treated HUVECs presented more intracellular actin stress fibers than the mock-treated control cells (Fig. 4) . A recent study by Menachem et al. indicated that the increased formation of intracellular stress fibers correlated with enhanced cell adhesion in mammary cells, whereas migrating cells had fewer stress fibers (52) . This provides another mechanism by which maspin inhibits endothelial cell migration.
In summary, this study provides direct evidence that maspin enhances HUVEC cell adhesion and restricts cell migration through the integrin signaling pathway. It regulates the activation of ILK and FAK and causes the reorganization of the actin cytoskeleton. Maspin prevents focal adhesion disassembly by increasing FAK Y397 phosphorylation resulting in impaired endothelial cell migration. 
